Detalhe da pesquisa
1.
An analysis of pharmaceutical experience with decades of rat carcinogenicity testing: support for a proposal to modify current regulatory guidelines.
Toxicol Pathol
; 39(4): 716-44, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21666103
2.
Strain-related differences in urine composition of male rats of potential relevance to urolithiasis.
Toxicol Pathol
; 37(3): 293-305, 2009 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-19380840
3.
Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist.
Toxicol Sci
; 100(1): 248-58, 2007 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-17675651
4.
Subchronic urinary bladder effects of muraglitazar in male rats.
Toxicol Sci
; 96(1): 58-71, 2007 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-17132713
5.
Rodent carcinogenicity profile of the antidiabetic dual PPAR alpha and gamma agonist muraglitazar.
Toxicol Sci
; 98(1): 258-70, 2007 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-17426106
6.
Dietary ammonium chloride for the acidification of mouse urine.
J Am Assoc Lab Anim Sci
; 48(2): 144-6, 2009 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-19383209
7.
Urine acidification has no effect on peroxisome proliferator-activated receptor (PPAR) signaling or epidermal growth factor (EGF) expression in rat urinary bladder urothelium.
Toxicol Appl Pharmacol
; 223(3): 246-56, 2007 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17663016
8.
Urothelial carcinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPAR alpha/gamma agonist: Evidence for urolithiasis as the inciting event in the mode of action.
Toxicol Pathol
; 34(7): 903-20, 2006.
Artigo
em Inglês
| MEDLINE | ID: mdl-17178691